These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 12738329)

  • 1. Hypofractionated radiotherapy for elderly or younger low-performance status glioblastoma patients: outcome and prognostic factors.
    Chang EL; Yi W; Allen PK; Levin VA; Sawaya RE; Maor MH
    Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):519-28. PubMed ID: 12738329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of hypofractionated intensity-modulated irradiation in the treatment of glioblastoma multiforme: preliminary results of a prospective trial.
    Sultanem K; Patrocinio H; Lambert C; Corns R; Leblanc R; Parker W; Shenouda G; Souhami L
    Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):247-52. PubMed ID: 14697445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival following CyberKnife radiosurgery and hypofractionated radiotherapy for newly diagnosed glioblastoma multiforme.
    Lipani JD; Jackson PS; Soltys SG; Sato K; Adler JR
    Technol Cancer Res Treat; 2008 Jun; 7(3):249-55. PubMed ID: 18473497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment outcomes for patients with glioblastoma multiforme and a low Karnofsky Performance Scale score on presentation to a tertiary care institution. Clinical article.
    Marina O; Suh JH; Reddy CA; Barnett GH; Vogelbaum MA; Peereboom DM; Stevens GH; Elinzano H; Chao ST
    J Neurosurg; 2011 Aug; 115(2):220-9. PubMed ID: 21548745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: a 6 year single institutional experience.
    Ciammella P; Galeandro M; D'Abbiero N; Podgornii A; Pisanello A; Botti A; Cagni E; Iori M; Iotti C
    Clin Neurol Neurosurg; 2013 Sep; 115(9):1609-14. PubMed ID: 23453151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).
    Mallick S; Kunhiparambath H; Gupta S; Benson R; Sharma S; Laviraj MA; Upadhyay AD; Julka PK; Sharma D; Rath GK
    J Neurooncol; 2018 Oct; 140(1):75-82. PubMed ID: 29936695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of hypofractionated radiation therapy in elderly patients with newly diagnosed glioblastoma with poor prognosis.
    Navarria P; Pessina F; Cozzi L; Tomatis S; Reggiori G; Simonelli M; Santoro A; Clerici E; Franzese C; Carta G; Conti Nibali M; Bello L; Scorsetti M
    Tumori; 2019 Feb; 105(1):47-54. PubMed ID: 30131010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors in glioblastoma multiforme patients receiving high-dose particle radiotherapy or conventional radiotherapy.
    Matsuda M; Yamamoto T; Ishikawa E; Nakai K; Zaboronok A; Takano S; Matsumura A
    Br J Radiol; 2011 Dec; 84 Spec No 1(Spec Iss 1):S54-60. PubMed ID: 21427185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome in elderly patients undergoing definitive surgery and radiation therapy for supratentorial glioblastoma multiforme at a tertiary care institution.
    Mohan DS; Suh JH; Phan JL; Kupelian PA; Cohen BH; Barnett GH
    Int J Radiat Oncol Biol Phys; 1998 Dec; 42(5):981-7. PubMed ID: 9869219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
    Prados MD; Wara WM; Sneed PK; McDermott M; Chang SM; Rabbitt J; Page M; Malec M; Davis RL; Gutin PH; Lamborn K; Wilson CB; Phillips TL; Larson DA
    Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):71-7. PubMed ID: 11163499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
    Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
    J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
    Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
    Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Standard dose and dose-escalated radiation therapy are associated with favorable survival in select elderly patients with newly diagnosed glioblastoma.
    Jackson WC; Tsien CI; Junck L; Leung D; Hervey-Jumper S; Orringer D; Heth J; Wahl DR; Spratt DE; Cao Y; Lawrence TS; Kim MM
    J Neurooncol; 2018 May; 138(1):155-162. PubMed ID: 29388034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO).
    Scoccianti S; Krengli M; Marrazzo L; Magrini SM; Detti B; Fusco V; Pirtoli L; Doino D; Fiorentino A; Masini L; Greto D; Buglione M; Rubino G; Lonardi F; Migliaccio F; Marzano S; Santoni R; Ricardi U; Livi L
    Radiol Med; 2018 Jan; 123(1):48-62. PubMed ID: 28879459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis.
    Panet-Raymond V; Souhami L; Roberge D; Kavan P; Shakibnia L; Muanza T; Lambert C; Leblanc R; Del Maestro R; Guiot MC; Shenouda G
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):473-8. PubMed ID: 18554821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperfractionated radiation therapy (HFX RT) followed by multiagent chemotherapy (CHT) in patients with malignant glioma: a phase II study.
    Jeremic B; Grujicic D; Antunovic V; Djuric L; Stojanovic M; Shibamoto Y
    Int J Radiat Oncol Biol Phys; 1994 Dec; 30(5):1179-85. PubMed ID: 7961028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma.
    Gerstein J; Franz K; Steinbach JP; Seifert V; Fraunholz I; Weiss C; Rödel C
    Radiother Oncol; 2010 Dec; 97(3):382-6. PubMed ID: 20850883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent accelerated hyperfractionated radiation therapy and carboplatin/etoposide in patients with malignant glioma: long-term results of a phase II study.
    Jeremic B; Shibamoto Y; Grujicic D; Stojanovic M; Milicic B; Nikolic N; Dagovic A; Aleksandrovic J
    J Neurooncol; 2001 Jan; 51(2):133-41. PubMed ID: 11386410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implant volume as a prognostic variable in brachytherapy decision-making for malignant gliomas stratified by the RTOG recursive partitioning analysis.
    Videtic GM; Gaspar LE; Zamorano L; Stitt LW; Fontanesi J; Levin KJ
    Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):963-8. PubMed ID: 11704318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients.
    Coughlin C; Scott C; Langer C; Coia L; Curran W; Rubin P
    Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1351-8. PubMed ID: 11121633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.